Receive Windhover's unique market insight fast with our free alert
service 'Windhover's Update', including the latest abstracts
and summaries from:
• IN VIVO
• Start-Up
• The RPM Report
• Medtech Insight
Sign up
now
|
|
|
Elsevier Business
Intelligence/Windhover
10 Hoyt Street
Norwalk, CT 06851
Tel: 203-838-4401
I-95 South:
Exit 16 (East Ave.). Take right at end. At 4th light, take left onto East Wall St. At 1st light, take right onto Main St. Take 2nd left onto Hoyt St. Windhover is second driveway on right. Door has blue awning.
|
I-95 North:
Exit 16 (East Ave.). Take left at end. At fifth light, take left onto East Wall St. At 1st light, take right onto Main St. Take 2nd left onto Hoyt St. Windhover is second driveway on right. Door has blue awning.
|
Merrit Parkway North:
Exit 39A (Route 7 Connector). Take Exit 1, and bear right at bottom of exit ramp. Make your first right onto Belden Ave. At the second traffic light make a left onto Cross St. Cross train tracks and make first right onto Hoyt Street. Windhover's visitor lot is located on your left hand side, across from McMahon Ford's lot. Door has blue awning.
|
Merrit Parkway South:
Exit 40A (Route 7 / Main Avenue). At bottom of exit ramp, take a right onto Route 7 South (Main Ave.). Continue on Rt. 7 South to Route 123 intersection (Dunkin Donuts landmark on right). Bear left onto Route 123 South (still considered Main Ave.). Continue to intersection of 123 South and Route 1. Continue straight one more block, Hoyt Street is on right after Family Diner. Windhover's visitor lot is second driveway on right, door has blue awning.
|
|
|
 |
|
 |
|
|
| |
 |
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets
Hit hard by late stage pipeline failures and the regulatory and reimbursement challenges of traditional primary care products, Big Pharmas are taking renewed interest in drugs for orphan diseases, where high unmet medical need offers the promise of premium pricing and there's potential to grow the market via approval in multiple indications. . . [MORE] (IN VIVO)
Despite Advances, Regenerative Medicine Faces Funding Crisis
Stem-cell and regenerative medicine firms are scrambling to find business models to harness the field's nascent, rapidly evolving science. Companies deep into clinical trials are still looking for pharma partnerships. . . [MORE] (Start-Up)
The Future of Drug-Eluting Stents Part II: Biodegradable Platforms
The safety profile of drug eluting stents appears to be improving with second and third-generation designs that utilize thinner struts (which are believed to reduce vessel injury and turbulent blood flow) and minimize or eliminate the polymer coating. . . [MORE] (Medtech Insight)
Health Reform in the Balance: What It Means for Biopharma
The long road to enacting health reform appeared to be close to an end with final negotiations taking place in the White House. But the Senate race for Ted Kennedy's open seat in Massachusetts has put the bill, and pharma's hard-fought concessions, in the breach. . . [MORE] (The RPM Report)
Read
more from the latest:
IN VIVO,
Start-Up,
The RPM Report,
Medtech Insight, "The Pink Sheet",
"The Pink Sheet" DAILY,
"The Rose Sheet",
"The Tan Sheet",
PharmAsia News,
Pharmaceutical Approvals Monthly, and
"The Gray Sheet".
|
|
|
|
| |
|
|
|
|
|
